A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki wyrażają zgodę na udział i stosują się do zasad badania.
- •Kobiety w wieku 18-75 lat.
- •Pacjentki z potwierdzonym histopatologicznie HER2-dodatnim rakiem piersi.
- •Rak jest we wczesnym stadium (II-III) przed leczeniem.
- •Pacjentki nie były wcześniej leczone na raka piersi.
- •Pacjentki zgadzają się na operację (mastektomię lub operację oszczędzającą pierś) po leczeniu.
- •Dobra ogólna kondycja fizyczna (parametr ECOG 0 lub 1).
- •Kobiety w wieku rozrodczym muszą stosować skuteczną antykoncepcję.
✗ Disqualifies
- •Rak piersi w stadium rozsianym (IV).
- •Rak obu piersi.
- •Wcześniejsza historia choroby nowotworowej piersi (z wyjątkiem niektórych łagodnych zmian).
- •Inne poważne choroby serca lub naczyń mózgowych w ostatnim czasie.
- •Problemy z rytmem serca lub wysokie ciśnienie krwi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 2, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (30)
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
Anhui Provincial Cancer Hospital
Hefei, China
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Medical University Union Hospital
Fuzhou, China
Guangdong Maternal and Child Health Center
Guangzhou, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China
Liuzhou People's Hospital
Liuzhou, China
Guangxi Medical University Cancer Hospital
Nanning, China
Hainan General Hospital
Haikou, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Xingtai People's Hospital
Xingtai, China
Harbin Medical University Cancer Hospital
Harbin, China
Anyang Cancer Hospital
Anyang, China
The First Affiliated Hospital of Henan University of science and technology
Luoyang, China
Henan Provincial People's Hospital
Zhengzhou, China
Hunan Cancer Hospital
Changsha, China
The Second Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Shaanxi Provincial People's Hospital
Xi'an, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Shandong Cancer Hospital
Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanxi Bethune Hospital
Taiyuan, China
Shanxi Cancer Hospital
Taiyuan, China
Sichuan Cancer Hospital
Chengdu, China
Tianjin Cancer Hospital
Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Trial contact
Sa Xiao, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.